Secukinumab

Global IL-17 Biologics Market Research Report 2023: Secukinumab, Ixekizumab, Bimekizumab, Brodalumab Market Insights and Forecasts, 2019-2022 and 2024-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 21, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Engineering, Psoriasis, Autoimmune disease, Ankylosing spondylitis, USD, Inflammation, Conditional sentence, Growth, Prevalence, Safety, Secukinumab, Patient, Statistics, Research report, Edition

The "Global IL-17 Biologics Market (2023 Edition): Analysis By Indication, By Drug (Secukinumab, Ixekizumab, Bimekizumab, Brodalumab), By Region, By Country: Market Insights and Forecast (2024-2030)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global IL-17 Biologics Market (2023 Edition): Analysis By Indication, By Drug (Secukinumab, Ixekizumab, Bimekizumab, Brodalumab), By Region, By Country: Market Insights and Forecast (2024-2030)" report has been added to ResearchAndMarkets.com's offering.
  • The Global IL-17 Biologics Market is expected to generate USD 10.9 Billion by the end of 2030, up from USD 4.37 Billion in 2022.
  • During the forecast period, 2024-2030, Global IL-17 Biologics is expected to expand at a CAGR of 12.3 %.
  • Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast.

Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and Utilization of IL-17 Inhibitors

Retrieved on: 
Monday, January 22, 2024
Need for Speed, Psoriatic arthritis, Patient, US FDA, RealTime, TNF, Joint, Rheumatology, Mechanism of action, HCP, Skin, Secukinumab, MOA, Physician, Pharmaceutical industry

However, recent years have witnessed a transformative shift in both the US and EU markets, as rheumatologists increasingly favor alternative mechanisms, notably IL-17 inhibitors.

Key Points: 
  • However, recent years have witnessed a transformative shift in both the US and EU markets, as rheumatologists increasingly favor alternative mechanisms, notably IL-17 inhibitors.
  • In contrast, within that timeframe, rheumatologists saw a preference for IL-17s more than double, indicating a noteworthy transformation in treatment preferences.
  • Over half of rheumatologists cite efficacy as their primary motive for favoring IL-17 inhibitors in PsA treatment, regularly underscoring the class’s success in treating both skin and joint manifestations.
  • As the treatment landscape for PsA undergoes dynamic changes, staying ahead of these shifting trends becomes essential for effective patient management and optimal treatment outcomes.

Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors

Retrieved on: 
Tuesday, November 14, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Secukinumab, Omalizumab, CSU, Inflammation, Multimedia, Patient, Novartis, Growth, Gesellschaft mit beschränkter Haftung, Pharmaceutical industry, Management, Arnout

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced the Board of Directors appointed Arnout Ploos van Amstel as Non-Executive Independent Director by way of co-optation.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced the Board of Directors appointed Arnout Ploos van Amstel as Non-Executive Independent Director by way of co-optation.
  • Mr. Ploos van Amstel replaces Dr. Garry Neil who will continue to support Zura Bio as an advisor on R&D matters.
  • View the full release here: https://www.businesswire.com/news/home/20231114200703/en/
    Arnout Ploos van Amstel (Photo: Business Wire)
    With a career spanning over three decades in the global biotech and pharmaceutical sector, Mr. Ploos van Amstel has built a successful track record in a wide variety of leadership positions.
  • “On behalf of Zura Bio’s Board of Directors, I am pleased to extend a warm welcome to Arnout as our newest addition to the Board," announced Dr. Someit Sidhu, CEO and Director of Zura Bio.

ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Tuesday, November 7, 2023
SLRN, Research, American College, MDA, Quality of life, Inflammation, Doctor of Philosophy, Hidradenitis suppurativa, Graves' ophthalmopathy, GxP, Disease, DRS, LOS, LEI, I&I, Secukinumab, Shep, Abscess, Shepherd (name), Axial spondyloarthritis, Amgen, Webcast, TED, Safety, Patient, D, Week, FRCP, MD, MRCP, Development, Growth, Clinical trial, Internal, Suicidal ideation, INC, Enthesitis, Psoriatic arthritis, FDA, CMC, Poster, National Center for Advancing Translational Sciences, Senior, Psoriasis, IL-17A, Cryptocurrency, Pharmaceutical industry, Medical device, Management

LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the third quarter ended September 30, 2023 and highlighted additional corporate updates and milestones.

Key Points: 
  • (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the third quarter ended September 30, 2023 and highlighted additional corporate updates and milestones.
  • For the quarter ended September 30, 2023, these expenses include a stock-based compensation expense of $11.7 million.
  • Net Loss: Net loss totaled $83.9 million for the third quarter of 2023, or $0.87 per share, compared to $14.4 million or $8.17 per share for the third quarter of 2022.
  • ET to review its third quarter 2023 financial results.

FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade

Retrieved on: 
Tuesday, October 31, 2023
Week, FDA, Psoriasis, HS, Flare, Harvard Medical School, Secukinumab, Beth Israel Deaconess Medical Center, MPH, Abscess, Doctor of Education, US Food Sovereignty Alliance, Hidradenitis suppurativa, Inflammation, HIV disease progression rates, EAST, Skin, International Association, Novartis, Disease, Medicine, Physician, Scar, Anxiety, Pain, Patient, Diagnosis, SUNRISE, Rheumatology, Pharmaceutical industry, Dermatology, MD

"This approval marks an important milestone for countless patients who have been faced with limited treatment possibilities and who now have a new option."

Key Points: 
  • "This approval marks an important milestone for countless patients who have been faced with limited treatment possibilities and who now have a new option."
  • "HS is one of the most devastating and exhausting skin diseases.
  • The pain of flares can be debilitating and limits my ability to work or participate in social activities.
  • "The approval of a new treatment option brings fresh hope to me and the HS community that we may find relief from the burden of the disease."

Montai Health Appoints Christian Antoni, M.D., Ph.D., as Company’s First Chief Medical Officer

Retrieved on: 
Tuesday, October 24, 2023
Conditional sentence, Translation, Secukinumab, Therapy, Infliximab, Human, International development, Flagship Pioneering, Leo Pharma, DJ Montay, Dupilumab, Drug development, Biology, Internal medicine, Sarilumab, Safety, AI, Patient, Rheumatology, Pharmaceutical industry

CAMBRIDGE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Montai Health, a company solving the chronic disease challenge by connecting complex biology to untapped human chemistry with AI to improve patients’ lives, today announced the appointment of Christian Antoni, M.D., Ph.D., as Chief Medical Officer. Dr. Antoni will lead the company’s development of scalable and efficient clinical operating capabilities to translate into the clinic a rapidly expanding pipeline of potential first-in-class oral therapies with an initial focus on chronic inflammatory and autoimmune diseases.

Key Points: 
  • Montai Health Appoints Christian Antoni, M.D., Ph.D., as Chief Medical Officer
    A rheumatologist by training, Dr. Antoni most recently was the Chief Development Officer at EQRx.
  • Montai’s CONECTA™ Platform is enabling breakthroughs in predictably developing first-in-class small-molecule medicines with potential for long-term safety and earlier intervention.
  • Changing this model has the potential to transform patient outcomes at scale.”
    Dr. Antoni completed his medical training and residency in internal medicine and rheumatology at Friedrich-Alexander University, Germany.
  • Dr. Antoni joins an industry-leading scientific and drug development team with decades of collective experience bringing novel, impactful medicines to the clinic across multiple therapeutic areas, including:

FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases

Retrieved on: 
Friday, October 6, 2023
Psoriatic arthritis, Ankylosing spondylitis, Rheumatology Research Foundation, AS, Rheumatology, Swedish Medical Center (Colorado), University, Novartis, Medicine, US Foods, EAST, FDA, Swedish Health Services, IV, Research, University of Washington School of Medicine, Patient, Pharmaceutical industry, Secukinumab, Immunology

Cosentyx is the only treatment approved in an IV formulation that specifically targets and blocks interleukin-17A (IL-17A), and the only non-tumor necrosis factor alpha (TNF-α) IV option available in all these indications.

Key Points: 
  • Cosentyx is the only treatment approved in an IV formulation that specifically targets and blocks interleukin-17A (IL-17A), and the only non-tumor necrosis factor alpha (TNF-α) IV option available in all these indications.
  • The IV formulation of Cosentyx offers patients a monthly 30-minute, weight-based dosing option, requiring no pre-medication and no lab monitoring.1 The new IV administration option will be available in Q4 of 2023.
  • "The approval of Cosentyx as an IV formulation is an important milestone for patients because it expands the treatment options available to them with a different mechanism of action than existing biologic IV therapies, along with the comfort and familiarity of an established treatment."
  • "At Novartis, we are committed to ensuring healthcare providers and patients have treatment options available to meet their unique needs.

Consecutive Use of TNF-Inhibitors for the Treatment of Psoriatic Arthritis at Lowest Point Recorded, as Use of Biologics with Alternate Mechanisms of Actions Continue to Grow, According to Spherix Global Insights

Retrieved on: 
Tuesday, October 3, 2023
Ixekizumab, Secukinumab, Amgen, NASA RealWorld-InWorld Engineering Design Challenge, MOA, TNF, Arthritis, Upadacitinib, Eli Lilly and Company, Risankizumab, Rheumatology, Patient, Psoriatic arthritis, Novartis, AbbVie, Algorithm, Physician, Need for Speed, Kwaku Amoa-Awuah, Safety, Guselkumab, Pharmaceutical industry, Apremilast

This results in a substantial patient population, with each physician handling an average of forty or more patients who switch their treatment on an annual basis.

Key Points: 
  • This results in a substantial patient population, with each physician handling an average of forty or more patients who switch their treatment on an annual basis.
  • Spherix Global Insights recently published its seventh annual Patient Chart Dynamix™: Triggers and Drivers in Psoriatic Arthritis, (previously RealWorld Dynamix: Switching in Psoriatic Arthritis).
  • Patients receiving TNFs are also provided an ample period of treatment in the first-line setting before considering a switch to an alternative therapy.
  • Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits.

ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development

Retrieved on: 
Tuesday, October 3, 2023
Secukinumab, SLRN, Bachelor, Royal college, FRCP, University, Senior, Physician, Bachelor of Medicine, Bachelor of Surgery, Psoriasis, CMO, Graves' ophthalmopathy, Psoriatic arthritis, Hidradenitis suppurativa, Dermatology, Patient, Novartis, Rheumatology, Shep, United Kingdom, LOS, MRCP, University of Zimbabwe, Pharmaceutical industry, Medical device, Medicine, Development, MD, Axial spondyloarthritis

LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Shephard (Shep) Mpofu, MD, MRCP, FRCP as Senior Vice President of Development. Dr. Mpofu will be responsible for leading clinical development as well as translational sciences and will also join the company’s Senior Leadership Team.

Key Points: 
  • Dr. Mpofu will be responsible for leading clinical development as well as translational sciences and will also join the company’s Senior Leadership Team.
  • “Shep is an internationally recognized immunologist and rheumatologist as well as an esteemed colleague.
  • Dr Mpofu is a United Kingdom General Medical Council Board-certified rheumatologist, who previously practiced at several institutions in the United Kingdom (UK) prior to joining industry.
  • “I am very excited to join the rapidly growing team at ACELYRIN and strongly believe in the company’s potential to advance transformative medicines for patients,” said Dr. Mpofu.

ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Monday, August 14, 2023
IPO, Axial spondyloarthritis, IV, Spermatogenesis, Nektar Therapeutics, Doctor of Philosophy, Pain, Graves' ophthalmopathy, Psoriatic arthritis, Dermatology, Teprotumumab, MD, Patient, Randomized controlled trial, Prurigo nodularis, DMC, Disease, Tissue, SLRN, Disability, Human, IL-17A, Data, Hearing, Uveitis, Rheumatology, Growth, FDA, Safety, D, Secukinumab, Neutropenia, Exercise, POC, Eosinophilic esophagitis, Allergy, B cell, AAD, Webcast, CFO, Enthesitis, LOS, Research, Hives, Therapy, Inflammation, Huber loss, CU, Data monitoring committee, TED, Pharmaceutical industry, Vaccine, Management, Rare-earth element, HS, Part, Hidradenitis suppurativa

LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the second quarter ended June 30, 2023 and highlighted additional recent corporate updates and milestones.   

Key Points: 
  • LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the second quarter ended June 30, 2023 and highlighted additional recent corporate updates and milestones.
  • Enrollment of the double-blind, placebo-controlled Part B of the Phase 2b/3 trial evaluating izokibep in HS completed ahead of schedule, accelerating anticipated top-line results into the third quarter 2023.
  • Net Loss: Net loss totaled $26.0 million for the second quarter of 2023, compared to $14.5 million for the second quarter of 2022.
  • ET to review its second quarter 2023 financial results.